2018 Pfizer Annual Review: Advancing Our Leading Jak Science

2018 Pfizer Annual Review: Advancing Our Leading JAK Science

2018 Pfizer Annual Review: Ushering in a New Era of R&D Productivity

Turning the Promise of Gene Therapy Into a Reality: Behind Our Science

Therapies for patients who progress on JAK inhibitors: imetelstat, navtemadlin, selinexor & TP-3654

VJHemOnc – Video Journal of Hematology & HemOnc

Q. How does Pfizer choose what medicines to focus R&D efforts on?

A Day in the Life of Pfizer Scientists

UConn Center for Career Development

SCIENCE. It works behind the scenes to put the world on stage.

Meet Gilles.

Saving lives with synthetic biology

CNN

Before it Became a Medicine - Video 1

10/29/2019 - Session 3: Matthew Ferber

NASEM Health and Medicine Division

SPARK Discoveries in Medical Research

La Jolla Institute for Immunology

Dr. Matthew Binnicker - A Q&A with a Mayo Clinic expert on monkeypox testing, more.

Reaction as US/UK scientists win Medicine prize

Debate: Survival benefit of JAK2 inhibitors in Myelofibrosis

Expert commentary: The FINCH 1 and FINCH 3 trials

Medicine Matters rheumatology

Pfizer in early-stage talks to acquire Seagen: Report

Webinar: Expanding on the Science: An Hour with Jack P. Shonkoff, M.D.

Webinar: "Research Year in Review" December 2016

The Michael J. Fox Foundation for Parkinson's Research